Health care stocks declined late Tuesday afternoon with the NYSE Health Care Index falling 1.3% and the Health Care Select Sector SPDR Fund (XLV) dropping 1.2%.
The iShares Biotechnology ETF (IBB) shed 1.9%.
In regulatory news, UnitedHealth Group's (UNH) OptumRx, CVS Health's (CVS) Caremark Rx and Cigna's (CI) Express Scripts marked up a number of specialty generic drugs at their affiliated pharmacies by hundreds or thousands of percent, the US Federal Trade Commission said Tuesday.
In corporate news, Johnson & Johnson's (JNJ) shares rose 0.1%. S&P Global Ratings said it placed almost all of the company's ratings on creditwatch with negative implications following its $14.6 billion deal to buy Intra-Cellular Therapies (ITCI).
Firefly Neuroscience (AIFF) shares surged 73%. The company said its BNA technology platform is able to assess a patient's biological brain age using cognitive data, potentially leading to a "scalable" approach to early screening for Alzheimer's patients.
Eli Lilly (LLY) shares tumbled 6.9% after the company lowered Q4 and full-year revenue expectations amid slower-than-expected growth in its US incretin division.
Pfizer (PFE) Chief Executive Officer Albert Bourla said the company's dispute with activist investor Starboard Value is over issues "on the margins" of its business and is not "an aggressive situation," Bloomberg reported. Pfizer shares fell 1.5%.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。